Blueprint Medicines Corp - Understand $bpmc stock

$BPMC Market Cap: $6.132 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$434.4M

TTM

Gross Margin

97.33%

TTM

Net Earnings

-$128.1M

TTM

Current Assets

$854.8M

Q3 2024

Current Liabilities

$257.7M

Q3 2024

Current Ratio

331.77%

Q3 2024

Total Assets

$1.200B

Q3 2024

Total Liabilities

$886.5M

Q3 2024

Book Value

$313.1M

Q3 2024

Cash

$89.36M

Q3 2024

P/E

-47.88

Dec 04, 2024 EST

Free Cash Flow

-$250.5M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$249.4M	$204.0M	$180.1M	$793.7M	$66.51M	$44.52M	$21.43M	$27.80M	$11.40M	$0.00	$0.00
YoY Change	22.22%	13.3%	-77.31%	1093.37%	49.39%	107.79%	-22.93%	143.86%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$249.4M	$204.0M	$180.1M	$793.7M	$66.51M	$44.52M	$21.43M	$27.80M	$11.40M	$0.00	$0.00
Cost Of Revenue	$8.540M	$17.81M	$17.93M	$425.0K
Gross Profit	$240.8M	$186.2M	$162.1M	$793.3M
Gross Profit Margin	96.58%	91.27%	90.04%	99.95%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$295.1M	$237.4M	$195.3M	$157.7M	$96.39M	$47.93M	$28.00M	$19.20M	$14.50M	$7.900M	$5.100M
YoY Change	24.34%	21.55%	23.8%	63.65%	101.11%	71.17%	45.83%	32.41%	83.54%	54.9%
% of Gross Profit	122.55%	127.47%	120.44%	19.88%
Research & Development	$427.7M	$477.4M	$601.0M	$326.9M	$331.5M	$243.6M	$144.7M	$81.10M	$48.60M	$31.80M	$15.90M
YoY Change	-10.41%	-20.57%	83.88%	-1.38%	36.05%	68.38%	78.41%	66.87%	52.83%	100.0%
% of Gross Profit	177.6%	256.37%	370.67%	41.2%
Depreciation & Amortization	$11.67M	$11.74M	$6.479M	$6.559M	$5.259M	$4.246M	$1.578M	$1.600M	$900.0K	$600.0K	$500.0K
YoY Change	-0.6%	81.12%	-1.22%	24.72%	23.86%	169.07%	-1.38%	77.78%	50.0%	20.0%
% of Gross Profit	4.84%	6.3%	4.0%	0.83%
Operating Expenses	$722.9M	$714.8M	$796.3M	$484.6M	$427.8M	$291.5M	$172.7M	$100.3M	$63.00M	$39.70M	$21.00M
YoY Change	1.13%	-10.24%	64.33%	13.27%	46.75%	68.84%	72.16%	59.21%	58.69%	89.05%
Operating Profit	-$482.0M	-$528.6M	-$634.2M	$308.7M
YoY Change	-8.81%	-16.65%	-305.43%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	-$18.79M	-$16.77M	$2.386M	$6.600M	$13.70M	-$100.0K	-$200.0K	-$500.0K	-$700.0K	-$500.0K	-$100.0K
YoY Change	12.08%	-802.72%	-63.85%	-51.82%	-13800.0%	-50.0%	-60.0%	-28.57%	40.0%	400.0%
% of Operating Profit				2.14%
Other Income/Expense, Net	-$19.74M	-$14.76M	$897.0K	$6.233M	$13.63M	$10.39M	$3.128M	$600.0K	-$400.0K	-$100.0K	$200.0K
YoY Change	33.71%	-1745.82%	-85.61%	-54.28%	31.25%	232.03%	421.33%	-250.0%	300.0%	-150.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	-$506.0M	-$552.3M	-$641.1M	$314.9M	-$347.7M	-$236.6M	-$148.1M	-$72.50M	-$52.80M	-$40.30M	-$20.90M
YoY Change	-8.38%	-13.85%	-303.56%	-190.58%	46.93%	59.79%	104.28%	37.31%	31.02%	92.82%
Income Tax	$1.000M	$5.236M	$3.001M	$1.058M						$0.00	$0.00
% Of Pretax Income				0.34%
Net Earnings	-$507.0M	-$557.5M	-$644.1M	$313.9M	-$347.7M	-$236.6M	-$148.1M	-$72.50M	-$52.80M	-$40.30M	-$20.90M
YoY Change	-9.06%	-13.44%	-305.2%	-190.28%	46.93%	59.76%	104.3%	37.31%	31.02%	92.82%
Net Earnings / Revenue	-203.3%	-273.24%	-357.67%	39.54%	-522.75%	-531.53%	-691.3%	-260.79%	-463.16%
Basic Earnings Per Share	-$8.37	-$9.35	-$11.01	$5.76	-$7.27	-$5.39
Diluted Earnings Per Share	-$8.37	-$9.35	-$11.01	$5.59	-$7.27	-$5.39	-$3.918M	-$2.636M	-$2.901M	-$1.562M	-$810.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$710.6M	$945.0M	$477.1M	$871.8M	$483.6M	$494.0M	$673.4M	$214.2M	$162.7M	$47.20M	$2.000M
YoY Change	-24.8%	98.06%	-45.27%	80.27%	-2.11%	-26.64%	214.38%	31.65%	244.7%	2260.0%
Cash & Equivalents	$71.29M	$119.7M	$209.9M	$684.6M	$113.9M	$68.10M	$400.3M	$52.10M	$162.7M	$47.20M	$2.000M
Short-Term Investments	$639.4M	$825.3M	$267.2M	$187.2M	$369.6M	$425.9M	$273.1M	$162.1M
Other Short-Term Assets	$33.35M	$35.02M	$18.06M	$22.00M	$9.800M	$5.600M	$12.10M	$2.700M	$4.300M	$1.000M	$500.0K
YoY Change	-4.78%	93.89%	-17.89%	124.49%	75.0%	-53.72%	348.15%	-37.21%	330.0%	100.0%
Inventory	$21.22M	$29.70M	$21.82M	$8.600M
Prepaid Expenses
Receivables	$43.18M	$36.94M	$37.03M	$25.30M	$23.40M	$200.0K	$0.00	$3.600M	$3.400M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$808.4M	$1.047B	$554.0M	$927.8M	$516.8M	$499.8M	$685.5M	$220.4M	$170.4M	$48.30M	$2.400M
YoY Change	-22.76%	88.92%	-40.29%	79.53%	3.4%	-27.09%	211.03%	29.34%	252.8%	1912.5%
Property, Plant & Equipment	$115.7M	$115.2M	$120.9M	$101.7M	$111.1M	$29.60M	$24.40M	$6.200M	$6.700M	$1.500M	$1.400M
YoY Change	0.39%	-4.69%	18.84%	-8.46%	275.34%	21.31%	293.55%	-7.46%	346.67%	7.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$56.53M	$133.5M	$557.5M	$677.9M	$64.40M	$0.00	$0.00	$54.10M
YoY Change	-57.65%	-76.06%	-17.76%	952.64%			-100.0%
Other Assets	$68.68M	$54.57M	$19.81M	$11.10M	$15.40M	$10.70M	$5.900M	$2.100M	$1.800M	$200.0K	$300.0K
YoY Change	25.84%	175.5%	78.46%	-27.92%	43.93%	81.36%	180.95%	16.67%	800.0%	-33.33%
Total Long-Term Assets	$240.9M	$303.3M	$698.2M	$790.6M	$190.9M	$40.30M	$30.20M	$62.40M	$8.500M	$1.600M	$1.700M
YoY Change	-20.58%	-56.57%	-11.69%	314.14%	373.7%	33.44%	-51.6%	634.12%	431.25%	-5.88%
Total Assets	$1.049B	$1.350B	$1.252B	$1.718B	$707.7M	$540.1M	$715.7M	$282.8M	$178.9M	$49.90M	$4.100M
YoY Change
Accounts Payable	$4.710M	$2.729M	$8.333M	$4.400M	$4.800M	$3.300M	$3.700M	$2.200M	$2.500M	$800.0K	$1.400M
YoY Change	72.59%	-67.25%	89.39%	-8.33%	45.45%	-10.81%	68.18%	-12.0%	212.5%	-42.86%
Accrued Expenses	$139.9M	$141.7M	$129.9M	$113.9M	$95.50M	$51.70M	$30.50M	$11.70M	$6.400M	$3.800M	$900.0K
YoY Change	-1.25%	9.07%	14.07%	19.27%	84.72%	69.51%	160.68%	82.81%	68.42%	322.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$30.28M	$16.85M					$1.500M	$2.600M	$3.300M	$1.700M	$700.0K
YoY Change	79.68%						-42.31%	-21.21%	94.12%	142.86%
Total Short-Term Liabilities	$214.9M	$183.2M	$149.8M	$130.8M	$106.5M	$60.30M	$42.90M	$28.50M	$18.60M	$6.800M	$3.200M
YoY Change	17.29%	22.35%	14.5%	22.82%	76.62%	40.56%	50.53%	53.23%	173.53%	112.5%
Long-Term Debt	$208.5M	$122.2M	$0.00	$0.00	$0.00	$0.00	$0.00	$1.500M	$4.100M	$7.300M	$2.200M
YoY Change	70.61%						-100.0%	-63.41%	-43.84%	231.82%
Other Long-Term Liabilities	$495.2M	$529.8M	$131.7M	$117.5M	$136.9M	$60.80M	$48.90M	$39.70M	$12.20M	$400.0K	$300.0K
YoY Change	-6.53%	302.17%	12.11%	-14.17%	125.16%	24.34%	23.17%	225.41%	2950.0%	33.33%
Total Long-Term Liabilities	$703.7M	$652.0M	$131.7M	$117.5M	$136.9M	$60.80M	$48.90M	$41.20M	$16.30M	$7.700M	$2.500M
YoY Change	7.93%	394.96%	12.11%	-14.17%	125.16%	24.34%	18.69%	152.76%	111.69%	208.0%
Total Liabilities	$918.6M	$835.2M	$281.5M	$248.3M	$243.3M	$121.1M	$91.80M	$69.70M	$34.90M	$14.50M	$5.600M
YoY Change	9.99%	196.72%	13.37%	2.06%	100.91%	31.92%	31.71%	99.71%	140.69%	158.93%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Basic Shares Outstanding	60.56M	59.64M	58.52M	54.53M	47.83M	43.87M	37.79M	27.49M
Diluted Shares Outstanding	60.56M	59.64M	58.52M	56.17M	47.83M	43.87M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $6.1315 Billion

About Blueprint Medicines Corp

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 638 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Industry: Pharmaceutical Preparations Peers: Cerevel Therapeutics Holdings, Inc. Beam Therapeutics Inc. ChemoCentryx, Inc. CYTOKINETICS INC Intellia Therapeutics, Inc. Natera, Inc. Mirati Therapeutics, Inc. PTC THERAPEUTICS, INC.